{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:17:26Z","timestamp":1775495846261,"version":"3.50.1"},"reference-count":31,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T00:00:00Z","timestamp":1471910400000},"content-version":"vor","delay-in-days":68,"URL":"http:\/\/diabetesjournals.org\/site\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of transdermal buprenorphine in patients with diabetic peripheral neuropathic pain (DPNP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial enrolled patients with type 1 or type 2 diabetes and stable glycemic control who had been experiencing moderate to severe DPNP for at least 6 months on maximal tolerated conventional therapy. Patients were randomly assigned to receive buprenorphine (5 \u03bcg\/h) or placebo patches. The dose was titrated to effect to a maximum of 40 \u03bcg\/h. Paracetamol was available as rescue analgesia. The severity of pain and other symptoms of DPNP were assessed daily in a patient diary and at clinic visits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>One hundred eight-six patients were enrolled, with 93 randomized to either buprenorphine or placebo. A high proportion of patients did not complete the study (buprenorphine 37 of 93, placebo 24 of 93). The main reason for premature withdrawal in the buprenorphine group was adverse events commonly due to untreated nausea and\/or vomiting. Among the per-protocol population, more patients in the buprenorphine group (86.3%) experienced a 30% reduction in average versus baseline pain at week 12 than those in the placebo group (56.6%, P &amp;lt; 0.001). A nonsignificant trend favored the buprenorphine group within the intention-to-treat analysis of the same end point (51.7% vs. 41.3%, P = 0.175).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Transdermal buprenorphine, when tolerated, is an effective therapy for DPNP and provides another option to manage this challenging painful condition. Nausea and constipation need to be managed proactively to optimize treatment outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-0123","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T03:19:43Z","timestamp":1466133583000},"page":"1493-1500","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":38,"title":["Transdermal Buprenorphine Relieves Neuropathic Pain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Diabetic Peripheral Neuropathic Pain"],"prefix":"10.2337","volume":"39","author":[{"given":"Richard W.","family":"Simpson","sequence":"first","affiliation":[{"name":"Eastern Clinical Research Unit, Eastern Health, Box Hill Hospital, Box Hill, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Wlodarczyk","sequence":"additional","affiliation":[{"name":"Consulting Services, New Lambton, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"key":"2022031300594816400_B1","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1111\/j.1526-4637.2006.00179.x","article-title":"Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review","volume":"8","author":"Barrett","year":"2007","journal-title":"Pain Med"},{"key":"2022031300594816400_B2","first-page":"151","article-title":"Treating diabetic peripheral neuropathic pain","volume":"82","author":"Lindsay","year":"2010","journal-title":"Am Fam Physician"},{"key":"2022031300594816400_B3","first-page":"412041","article-title":"Pathogenesis of painful diabetic neuropathy","volume":"2014","author":"Aslam","year":"2014","journal-title":"Pain Res Treat"},{"key":"2022031300594816400_B4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031300594816400_B5","first-page":"289","article-title":"Update on the management of diabetic polyneuropathies","volume":"4","author":"Shakher","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031300594816400_B6","first-page":"CD010567","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","volume":"11","author":"Wiffen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031300594816400_B7","first-page":"CD007115","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","volume":"1","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031300594816400_B8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"key":"2022031300594816400_B9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","article-title":"Algorithm for neuropathic pain treatment: an evidence based proposal","volume":"118","author":"Finnerup","year":"2005","journal-title":"Pain"},{"key":"2022031300594816400_B10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacological profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Pract"},{"key":"2022031300594816400_B11","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain - safety aspects","volume":"2","author":"Likar","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"2022031300594816400_B12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis","year":"2012","journal-title":"J Support Oncol"},{"key":"2022031300594816400_B13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br J Anaesth"},{"key":"2022031300594816400_B14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"key":"2022031300594816400_B15","first-page":"187","article-title":"Implications of intrathecal pertussis toxin animal model on the cellular mechanisms of neuropathic pain syndrome","volume":"41","author":"Wen","year":"2003","journal-title":"Acta Anaesthesiol Sin"},{"key":"2022031300594816400_B16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pain.2005.06.030","article-title":"Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model","volume":"118","author":"Koppert","year":"2005","journal-title":"Pain"},{"key":"2022031300594816400_B17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1213\/01.ANE.0000145066.06538.20","article-title":"Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies","volume":"100","author":"Likar","year":"2005","journal-title":"Anesth Analg"},{"key":"2022031300594816400_B18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1533-2500.2010.00434.x","article-title":"Transdermal buprenorphine for central neuropathic pain: clinical reports","volume":"11","author":"Guetti","year":"2011","journal-title":"Pain Pract"},{"key":"2022031300594816400_B19","first-page":"11","article-title":"Transdermal buprenorphine in the management of neuropathic pain","volume":"11","author":"Rodriguez-Lopez","year":"2004","journal-title":"Rev Soc Esp Dolor"},{"key":"2022031300594816400_B20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1185\/030079905X53315","article-title":"Transdermal buprenorphine in clinical practice\u2014a post-marketing surveillance study in 13,179 patients","volume":"21","author":"Griessinger","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2022031300594816400_B21","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"2022031300594816400_B22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/11596280-000000000-00000","article-title":"Combination therapy for neuropathic pain: a review of current evidence","volume":"25","author":"Vorobeychik","year":"2011","journal-title":"CNS Drugs"},{"key":"2022031300594816400_B23","doi-asserted-by":"crossref","first-page":"g6380","DOI":"10.1136\/bmj.g6380","article-title":"Opioids for low back pain","volume":"350","author":"Deyo","year":"2015","journal-title":"BMJ"},{"key":"2022031300594816400_B24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/14656566.2011.536335","article-title":"Opioids in chronic non-cancer pain","volume":"12","author":"Chan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"2022031300594816400_B25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","article-title":"Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone)","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain Pract"},{"key":"2022031300594816400_B26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0140-6736(02)07816-9","article-title":"Blinding in randomised trials: hiding who got what","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"key":"2022031300594816400_B27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/096228029700600202","article-title":"Regression towards the mean, historically considered","volume":"6","author":"Stigler","year":"1997","journal-title":"Stat Methods Med Res"},{"key":"2022031300594816400_B28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fpubh.2013.00029","article-title":"Assessing the relationship between the baseline value of a continuous variable and subsequent change over time","volume":"1","author":"Chiolero","year":"2013","journal-title":"Front Public Health"},{"key":"2022031300594816400_B29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2022031300594816400_B30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"2022031300594816400_B31","first-page":"CD008943","article-title":"Combination pharmacotherapy for the treatment of neuropathic pain in adults","volume":"7","author":"Chaparro","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/9\/1493\/625927\/dc160123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/9\/1493\/625927\/dc160123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T04:34:29Z","timestamp":1647146069000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/9\/1493\/37048\/Transdermal-Buprenorphine-Relieves-Neuropathic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,6,16]]},"published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-0123","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]}}}